Bayer reportedly close to diabetes device sale worth up to $2.3B

Bayer is reportedly near a deal to sell its diabetes device business to KKR-backed Panasonic Healthcare for up to €2 billion ($2.3 billion). The proposed sale is part of the German drug giant's efforts to zero in on its more successful life sciences businesses; the company also plans to spin off its MaterialScience division. Report